• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·7575.T
Share

Japan Lifeline Co., Ltd. Stocks

¥ 1522Last Updated 11.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

¥ 685.16M

¥ 1522
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 7575.T is 1576 and suggests 5.69% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026